Preclinical evaluation of the α-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3555-3561

  Miederer, Matthias ^a   Henriksen, Gjermund ^a   Alke, Andrea ^a   Mossbrugger, Ilona ^b   Quintanilla Martinez, Leticia ^b   Senekowitsch Schmidtke, Reingard ^a   Essler, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] ACTINIUM AC 225; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] LUTETIUM LU 177; ACTINIUM 225; LUTETIUM 177; OCTREOTIDE[3 TYROSINE]; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; (DOTA(0) PHE(1) TYR(3))OCTREOTIDE; (DOTA(0)-PHE(1)-TYR(3))OCTREOTIDE; DRUG DERIVATIVE; OCTREOTIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; HISTOPATHOLOGY; ISOTOPE LABELING; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; EXPERIMENTAL NEOPLASM; RADIATION EXPOSURE;

ALPHA PARTICLES; ANIMALS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; RECEPTORS, SOMATOSTATIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 50349089716     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4647     Document Type: Article

References (19)

1. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717-51.
2. Schupak KD, Wallner KE. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int J Radiat Oncol Biol Phys 1991;20:489-95.
3. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007;46:723-34.
4. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941 -5.
5. Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of α particles. III. Cell inactivation by α-particle traversals of the cell nucleus. Radiat Res 1991;128:204-9.
6. Nikula TK, McDevitt MR, Finn RD, et al. α-Emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 1999;40:166-76.
7. Couturier 0, Supiot S. Degraef-Mougin M. et al Cancer radioimmunotherapy with α-emitting nuclides Eur J Nucl Med Mol Imaging 2005;32:601 -14
8. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with α-emitting nuclides. Eur J Nucl Med 1998;25:1341-51.
9. Beck R, Seidl C, Pfost B, et al. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice. Cancer Sci 2007;98:1215- 22
10. McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA. Design and synthesis of 225Ac radioimmunophar-maceuticals. Appl Radiat Isot 2002;57:841 - 7
11. Miederer M, McDevitt MR, Sgouros G. Kramer K. Cheung NK, Scheinberg DA. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med 2004;45:129-37.
12. Miederer M, Scheinberg DA, McDevitt MR. Realizing the potential of the Actinium-225 radionuclide generator in targeted α-particle therapy applications. Adv Drug Deliv Rev. In press 2008.
13. Taylor JE, Theveniau MA, Bashirzadeh R, ReisineT, Eden PA. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 1994;15:1229-36.
14. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537-40.
15. Norenberg JP, Krenning BJ, Konings IR, et al. 213Bi-[DOTA0, Tyr3] octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin Cancer Res 2006;12:897-903.
16. Nayak TK, Norenberg JP, Anderson TL, Prossnitz ER, Stabin MG, Atcher RW. Somatostatin-receptor-targeted α-emitting 213Bi is therapeutically more effective than β(-)-emitting 177 Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol 2007;34:185-93.
17. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal up-take of radiolabeled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9-15.
18. Jaggi JS, Kappel BJ, McDevitt MR, et al. Efforts to control the errant products of a targeted in vivo generator. Cancer Res 2005;65:4888-95.
19. Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA, Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys 2006;64:1503-12.